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Nanoparticle size inﬂuences the proliferative
responses of lymphocyte subpopulations†
Xavier le Gue´vel,*a Francisca Palomares,b Maria J. Torres,bc Miguel Blanca,bc
Tahia D. Fernandezb and Cristobalina Mayorgabc
12 nm gold nanoparticles induce cell mediated responses accompanied by inﬂammatory natural killer cell
stimulation, whereas 2 nm gold nanoparticles are more eﬃciently uptaken without inducing dendritic cell
maturation or lymphocyte proliferation.
The use of engineered nanoparticles for immunotherapy has
been extensively investigated, notably towards the development
of novel vaccines.1–5 By tailoring their physicochemical proper-
ties such as size, shape, and surface chemistry, nanoparticles
are able to positively or negatively modulate immune responses
via antigen presenting cells (APCs).2–4,6,7 This strategy promises
the development of novel nanovaccines that are able to modify
adaptive immune responses for the treatment of cancer or auto-
immune diseases.6,8–10 For example, increased nanoparticle
surface hydrophobicity has been shown to progressively induce
acute inammation in both in vitro and in vivo models.7
Nanoparticle shape can also aﬀect immune responses, for
example rod and star shapes elicit enhanced immune
responses, although their clearance may have toxic eﬀects.11,12
Another parameter that has been studied is the inuence of
spherical particle sizes from 40 nm to one micron with larger
nanoparticles favouring the induction of cell-mediated
responses and a higher cell uptake for particles smaller than
500 nm.13,14
In this study we chose gold particles with two diﬀerent sizes
at the lower end of the nanosize window: 2 nm so-called
nanoclusters (NCs)15,16 and 12 nm nanoparticles (NPs) both
protected by the same glutathione (GSH) tripeptide ligand. GSH
is an antioxidant which oﬀers the advantage of improving the
colloidal stability of particles in complete medium, while its
free carboxyl groups allow molecules to be conjugated onto the
surface.18 Dendritic cells (DCs), an important type of APC,
modulate both eﬀector and tolerance responses by presenting
MHC Class II-bound antigens to T lymphocytes while secreting
co-stimulatory factors that depend on their maturational
state.19–21 Our aim was to determine if size (<15 nm) aﬀects
particle uptake by dendritic cells, and whether it alters their
eﬀects on the immunological system as judged by changes to
DC maturation and the inammatory responses of diﬀerent
lymphocyte subpopulations. DC maturation was evaluated by
cell surface markers and cytokine secretion, while inammatory
responses was followed by looking at the proliferation of
diﬀerent lymphocyte subpopulations including CD4+ and CD8+
T and Natural Killer (NK) cells, as well as cytokine production.
Particles synthesis was conducted in aqueous solution using
gold salt and GSH, with sodium borohydride also used for the
larger particles (see ESI for details†). Particle size was deter-
mined by dynamic light scattering (Fig. 1a) and electron
microscopy (Fig. S1†) indicating high monodispersity for NCs
(B ! 2 nm) and NPs (B ! 12 nm). We used thermal analysis to
estimate ligand content per particle (based on the ligand's
organic moiety) nding around 56% and 19% for NCs and NPs,
respectively. No signicant aggregation of NCs or NPs was
observed aer incubation in complete medium (RPMI1640 +
10% serum) for 48 hours. Absorbance analysis revealed that NPs
possess the typical plasmon band at 520 nm. In contrast, NCs
Fig. 1 (a) Size analysis by dynamic light scattering of GSH ligand-
stabilised NCs and NPs in aqueous solution. (b) Inductively coupled
plasma high-resolution mass spectrometry (ICP-HRMS) measure-
ments of DCs incubated with NCs or NPs (10 mg mL"1 in complete
medium) for 48 hours.
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exhibited strong UV absorption (Fig. S2†) and intense photo-
luminescence in the orange-red window (lmax ¼ 610 nm)22
(Fig. S3†), which originate from the strong quantum conne-
ment seen in species of this size and metal–ligand
interactions.23–26
NC and NP cytotoxicity was evaluated in human monocyte-
derived dendritic cells (DCs) via specic Live/Dead cell stain-
ing and ow cytometry. Incubation for 48 hours with concen-
trations up to 25 mg mL"1 of NCs, NPs or equivalent
concentrations of free GSH ligand had no signicant eﬀect on
cytotoxicity compared to non-treated cells (Fig. S4†). Cellular
particle uptake was quantied by inductively coupled plasma
high-resolution mass spectrometry (ICP-HRMS) aer incu-
bating DCs with NCs or NPs (10 mg gold per mL) for 48 hours
(Fig. 1b). We found that NC uptake in terms of gold particles per
cell was 67 times higher than that of NPs, indicating highly
eﬃcient internalisation of NCs into DCs. This observation is in
agreement with previous studies showing stronger uptake of
small particles, most likely related to their high diﬀusion
capacity.27,28 The internalisation of NCs and NPs in the cyto-
plasm and close to the membrane could be readily observed by
the presence of dark accumulations under bright-eld illumi-
nation, and by photoluminescent emissions upon two-photon
excitation (lexc. ¼ 720 nm) (Fig. S5†).
One of the rst response steps in the immune response to an
antigen by a dendritic cell is its maturation. Mature DCs are
characterised by the loss of their ability to internalise antigens,
while upregulating MHC Class II molecules and co-stimulatory
factors such as CD80 and CD86, thereby acquiring the capacity
to present antigens to na¨ıve T-cells and inducing diﬀerent
immunological responses.29–31 Thus, to understand how particle
size might aﬀect DC-mediated immune responses, we incu-
bated immature DCs with NCs and NPs (1 to 25 mg mL"1 of gold
in complete medium) for 48 hours. The maturational status of
DCs was then evaluated using ow cytometry-based detection of
CD80 and CD86 surface antigens. Positive (lipopolysaccharide;
LPS) and negative (free GSH ligand in eq. ligand concentration)
controls were also included. Results depicted in Fig. 2a show
that incubation with NPs signicantly increased the expression
of both CD80 and CD86 in a dose dependant manner, sug-
gesting the induction of DC maturation. In contrast, no DC
maturation i.e. no increase in expression above the MI > 2
threshold, was seen for cells cultured in the presence of NCs or
with free ligand alone. We were surprised to observe no
signicant increase in DCmaturation following incubation with
NCs, especially as they were more strongly uptaken than NPs.
Recent studies have shown that particle uptake does not always
correlate with functional changes in human dendritic cells in
vitro.32,33 Dissimilarities between the two classes of particle
might be related to diﬀerences in the endocytic pathways
involved in their uptake. Further studies will be required to
understand the molecular basis for the diﬀerent interactions
between DCs and NCs/NPs.
DC maturation tends to induce high levels of MHC mole-
cules and the secretion of sets of cytokines that play a key role in
activating na¨ıve T cells and the launch of primary immune
responses.8 To further characterise DC maturation following
incubation with NPs or NCs, we measured the pattern of cyto-
kine release into the culture supernatant in each case. Our
analysis of cytokine production (IL12, IFNg, IL4, IL13, IL10,
IL17), depicted in Fig. 2b and S6,† detected signicant increases
in IL12, IFNg and IL10 in response to NPs, in a dose dependent
manner. Elevated expression of IL12 and IFNg suggest that NPs
induce an inammatory DC response20 while no signicant
cytokine production was detected using NCs or free ligand
consistent with the absence of DC maturation following these
treatments.
Our nding that particle size aﬀects DC maturation suggests
that it may also aﬀect subsequent steps in the immunological
response, where mature DCs interact with lymphocyte sub-
populations. To examine this possibility we examined how
DCs incubated with NCs or NPs can subsequently induce
changes in lymphocyte proliferation and activity in terms of
cytokine production. Diﬀerent T lymphocyte and NK cell
subpopulations have been reported to shape immunological
responses in diﬀerent ways. T helper cells can be divided into
Th1, Th2, Th17 and Treg subpopulations depending on their
cytokine production.34 Th1 cells have been implicated in
responses to infectious and inammatory disorders.35 Th2 cells
are essential for the induction of allergy and asthma.36 Th17
cells are related to neutrophil activation and implicated in
several autoimmune diseases.34,36 Treg cells are involved in the
regulation of inammatory eﬀector cells. Moreover, two NK cell
subpopulations have been described: (i) CD56dim cells (the
main NK population in peripheral blood) expressing high levels
of CD16 and perforin, which mediate cytotoxic activity, and (ii)
CD56bright cells usually associated with the inammatory NK
population37 that produces high levels of IFNg.38
Fig. 2 (a) Maturation status (CD80 and CD86 markers) expressed as
a maturation index (MI), and (b) cytokine secretion* (IFN-g, IL12, IL10)
of DCs incubated with NCs, NPs, free GSH (1 to 25 mg mL"1 in
complete medium) and LPS (lipopolysaccharide) as positive control for
48 h. * – tested at 10 and 25 mg mL"1 of NCs, NPs, or eq. conc. of free
GSH. Statistical comparisons were performed using the Wilcoxon test
for related samples. The Bonferroni correction was applied for
comparison of three groups. Statistical diﬀerences were considered
signiﬁcant when p < 0.025.
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In this work, we carried out co-culture experiments where T
and Natural Killer (NK) cell populations were incubated with NC
or NP-pre-treated DCs to determine their antigen presenting
activity by measuring proliferation and cytokine release. DCs
were pre-incubated with NCs, NPs or free ligand at diﬀerent
concentrations (1 to 25 mg gold per mL in complete medium or
equivalent ligand concentrations), washed and then co-cultured
over 6 days. No signicant cytotoxicity was observed regardless
of the particle concentration used (Fig. S4†). Lymphocyte
proliferation, expressed as a proliferation index (PI), was eval-
uated by measuring the frequency of cells with reduced levels of
a uorescent tracer (CFSEdim cells) together with specic
subpopulation markers. Results indicated increases in the PI of
T lymphocytes (CD3+ CFSEdim), T helper (CD4+ CFSEdim) and NK
(CD56+ CFSEdim) cells following incubation with high NP
concentrations (Fig. 3a). No proliferative response increases (PI
< 2) were detected for cytotoxic T cells (CD8+) incubated with
NP-treated DCs, or following co-culture with DCs treated with
NCs or free GSH.
To better understand the immunological eﬀect of NP-
stimulated DCs, we set out to identify the diﬀerent subpopula-
tions involved in T and NK cell proliferation. Our results indi-
cate non-specic proliferative responses by Treg and Th17
populations aer stimulation with the diﬀerent particles since
no diﬀerences in their proliferative response were found
compared to GSH-stimulated cells (Fig. S7†).
The production of IFNg by lymphocytes not secreting IL4
and IL13 (Fig. S6†) following the presentation of NP pre-treated
DCs could also be associated with the induction of a prolifera-
tive CD4 sub-population corresponding to a cell-mediated
response (Th1) and matches the cytokine release observed
during NP-induced DC maturation.
Regarding NK cells, signicantly increased proliferation of
the CD56bright NK subpopulation combined with elevated IFNg
production was observed in response to co-culture with NP-
treated DCs in a dose dependent manner (Fig. 4a and b).
Importantly, there was no increase in granzyme B secretion,
a cytotoxic mediator released from cytoplasmic granules in
cytotoxic T and NK cells, following NP-treated DC co-culture
(Fig. 4c). These two observations are consistent with the pres-
ence of high levels of inammatory NK cells (CD56bright).
Our lymphocyte proliferative data indicate that the increase
in Th1 lymphocytes and CD56bright NK cells is related to the
production of IFNg and IL12 combined with undetectable levels
of IL4 and IL13 (Fig. 2b and S6†) following NP stimulation.
These results suggest that NP treatment promotes innate
immunity-type responses from NK cells.
The results obtained in this work are in agreement with
a previous study suggesting crosstalk between innate and
adaptive immune systems involving interactions between
DCs and NK cells.39 This concept is supported by the
demonstration that DCs can activate NK cells, while activated
NK cells can inuence DCmaturation or direct their cytotoxic-
eﬀects specically towards immature DCs, which would
hamper tolerant responses.40,41 Thus, crosstalk between DC
and NK cell populations is likely to be a key factor in inu-
encing the balance between tolerant and immunologic
responses.
By employing the same surface chemistry for both particles,
this study clearly demonstrates the strong inuence of particle
Fig. 3 Proliferative responses of diﬀerent lymphocyte subpopulations
(CD3, CD4, CD8, and CD56 markers), expressed as a proliferation
index (PI), with Peripheral Blood Mononuclear Cells (PBMCs) + DCs
incubated with NCs, NPs or GSH (1 to 25 mg mL"1 in complete
medium) for 6 days. Statistical comparisons were performed using the
Wilcoxon test for related samples. The Bonferroni correction was
applied for comparison of three groups. Statistical diﬀerences were
considered signiﬁcant when p < 0.025.
Fig. 4 (a) Proliferative responses of diﬀerent lymphocyte NK
subpopulations (CD56dim and CD56bright cells); (b) cytokine INFg
secretion levels during the proliferative lymphocyte experiments*, (c)
granzyme B assay on peripheral blood lymphocytes*. Proliferation
positive control: PHA: phytohemagglutinin. * only at 10 and 25 mg
mL"1 of NCs, NPs, and eq. free GSH. Statistical comparisons were
performed using theWilcoxon test for related samples. The Bonferroni
correction was applied for comparison of three groups. Statistical
diﬀerences were considered signiﬁcant when p < 0.025.
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size on DC uptake, DC maturation, the proliferative response of
T lymphocytes and the presence of inammatory NK cells.
The ultra-small particles (NCs, B ! 2 nm) were eﬃciently
uptaken by DCs but did not induce maturation or lymphocyte
proliferation. These observations seem to agree with studies
demonstrating high passive targeting and clearance of NCs
stabilised with GSH.17,42 The presence of functional GSH
carboxyl groups on the NC surface should enable the conjuga-
tion of biomolecules such as antigens and, in the absence of
carrier-associated immunogenic reactions, represents a good
candidate antigen delivery system. In contrast, the slightly
bigger nanoparticles (NPs, B ! 12 nm) caused DC maturation
and T lymphocyte proliferation associated with cell-mediated
immunity-type responses and the production of inammatory
NK cells in a dose dependent manner. These results are of
considerable interest as this subpopulation is a potential target
for anti-tumour immunotherapy, inammatory response limi-
tation and the treatment of autoimmune disorders.43 Indeed,
this NK cell sub-type represents a relatively small proportion of
Peripheral Blood Mononuclear Cells (PBMCs) but presents the
advantage of being one of the most eﬃcient cytokine
producers37 and is able to shape the adaptive response. Indeed,
Caliguri et al. undertook a comprehensive investigation of the
role of NK sub-types, demonstrating the unique innate immu-
noregulatory role of the CD56bright subpopulation by producing
specic types of cytokines.20 Because lowered NK activity in
peripheral blood has been associated with elevated cancer risk
in patients, strategies involving enhancement of NK cells for
anti-tumour treatment are currently being investigated.44,45
As previously discussed by Drobrovolskaia et al.,46 it remains
diﬃcult to demonstrate clear relationships between the physi-
cochemical properties of particles and their eﬀects on immune
responses due to the complex interactions between cytokines
and numerous other cellular processes such as multiple cell
uptake mechanisms. Diﬀerent particle types have been shown
to elicit Th1 responses but the contribution of inammatory NK
cells accompanied by high IFNg levels in response to 12 nm
nanoparticles potentially opens new avenues for immunother-
apeutic treatments of cancer or infections.
Conclusions
In summary, we have shown how particle size in a narrow size
range (1 to 15 nm) strongly inuences cell uptake and immune
responses with ultra-small size (<2 nm) leading to high cellular
uptake without DC maturation and therefore lymphocyte
proliferation. In contrast, bigger particles (12 nm) elicited DC
maturation with a cell-mediated immunity pattern (Th1) and
the proliferation of T helper lymphocytes in a concentration
dependent manner. Moreover, we found that 12 nm NPs
induced the proliferation of inammatory NK cells with high
levels of pro-inammatory cytokine IFNg secretion, suggesting
that it might represent a tool for shaping and inuencing
adaptive immunity to ght cancer or infectious diseases. Our
results underline the importance of examining diﬀerent particle
sizes in the 1–15 nm nanometric window in order to ne tune
their eﬀects on the immune system.
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